代谢综合征而非肥胖对开放主髂动脉旁路术后结局产生不良影响
该回顾性队列纳入2004至2015年154例因主髂动脉闭塞性疾病行开放旁路手术的患者,代谢综合征采用WHO标准定义。代谢综合征是再干预的独立预测因素(HR 1.8,P=0.036),而肥胖本身不是再干预危险因素且与长期死亡率降低相关,支持「肥胖悖论」。
要点
- 代谢综合征是开放主髂动脉旁路术后再干预的独立危险因素(HR 1.8,P=0.036)。
- 肥胖本身不是再干预危险因素,且非肥胖是长期死亡的独立危险因素。
- 代谢综合征患者1年和5年再干预率分别为33.0±6.8%和56.1±7.9%,显著高于无代谢综合征者。
核心结论
- 肥胖本身不是开放主髂动脉旁路术后再干预的危险因素,且为死亡的保护因素,支持「肥胖悖论」。
- 代谢综合征整体与不良事件相关,是再干预的独立预测因素,但其单个组分不增加再干预风险。
- 旁路移植血管通畅率和主要截肢率在代谢综合征、肥胖及非代谢综合征患者间无显著差异。
研究设计与样本
- 回顾性队列研究,纳入2004至2015年因主髂动脉闭塞性疾病行开放旁路手术的154例患者。
- 排除血管腔内修复及以动脉瘤性疾病为主要治疗指征的患者。
- 代谢综合征采用WHO标准定义:糖尿病加血脂异常、高血压和肥胖(BMI>30 kg/m2)中至少2项。
- 采用分层Kaplan-Meier和多因素Cox回归分析长期死亡率和再干预率等结局。
主要发现
- 中位年龄60岁(IQR 53-68),中位肾小球滤过率76.1 mL/min(IQR 54-102),女性占58%。
- 53例(4%)存在代谢综合征,14例(9%)为肥胖但无代谢综合征。
- 1年和5年原发性旁路移植物通畅率分别为89.0±2.7%和77.4±4.1%,各组间无显著差异。
- 全队列1年和5年再干预率分别为25.3±3.7%和40.6±4.7%。
- 代谢综合征与无代谢综合征者1年和5年再干预率分别为33.0±6.8% vs 21.1±4.2%和56.1±7.9% vs 30.7±5.4%(log-rank P=0.003)。
临床怎么用
- 对合并代谢综合征的主髂动脉闭塞患者,术后应加强再干预风险的监测与随访。
- 肥胖本身不应作为拒绝开放主髂动脉旁路手术的依据,其与再干预风险无关且与死亡风险降低相关。
- 评估代谢综合征整体而非单个组分,以识别再干预高危患者。
局限性
- 单中心回顾性设计,样本量154例,代谢综合征组仅53例,肥胖无代谢综合征组仅14例。
- 代谢综合征定义采用WHO标准,不同定义可能影响结果外推。
- 原文未报告随访时长、失访率及多因素模型的具体协变量列表。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although the incident risk of peripheral artery disease increases in patients with metabolic syndrome, several authors report favorable outcomes in obese patients after arterial bypass surgery. We examine the effect of the so-called "obesity paradox" and metabolic syndrome on outcomes after open aortoiliac bypass surgery. METHODS: We identified patients between 2004 and 2015 who had open surgical bypass for aortoiliac occlusive disease. We excluded patients with endovascular repair and those treated primarily for aneurysmal disease. Variables that were analyzed included preoperative medical history, Trans-Atlantic Inter-Society Consensus Document on Management of Peripheral Arterial Disease II classification, Rutherford classification, intra-operative, and postoperative outcomes. Metabolic syndrome was defined by World Health Organization criteria: diabetes and 2 or more of dyslipidemia, hypertension, and obesity (body mass index > 30 kg/m2). Data were analyzed by stratified Kaplan-Meier and multiple Cox regression for outcomes including long-term mortality and reintervention rate. RESULTS: There were 154 open bypass surgery patients during the study period with a median age of 60 years (interquartile range [IQR] 53-68), median glomerular filtration rate 76.1 mL/min (IQR 54-102), and 58% female prevalence. In all, 53 patients had metabolic syndrome (4%), and 14 patients (9%) were obese but did not have metabolic syndrome. Primary bypass graft patency was 89.0 ± 2.7% at 1 year and 77.4 ± 4.1% at 5 years and was not significantly different between metabolic syndrome, obese, and nonmetabolic syndrome patients. Reintervention rate for the entire cohort was 25.3 ± 3.7% at 1 year and 40.6 ± 4.7% at 5 years. In those with and without metabolic syndrome, reintervention rate at 1 and 5 years was 33.0 ± 6.8% vs. 21.1 ± 4.2% and 56.1 ± 7.9% vs. 30.7 ± 5.4%, respectively (log-rank P = 0.003). In multivariable analyses, metabolic syndrome (hazard ratio [HR] 1.8, P = 0.036) and critical limb ischemia (CLI) (HR: 3.2, P = 0.001) were the only independent predictors of reintervention. Neither obesity nor the individual components comprising metabolic syndrome was a risk for reintervention. Multivariate analysis demonstrated age, female gender, CLI, and nonobesity as the independent risk factors for long-term mortality. CONCLUSIONS: Our study supports the "obesity paradox" that obesity by itself is not a risk factor for reintervention and was a protective factor for mortality after open aortoiliac bypass surgery. Bypass graft patency and major amputation rates were not affected. Although the individual components do not predispose to worse outcome, metabolic syndrome is a constellation of factors that, together, are associated with adverse events.
引用
- Tanaka A, Perlick A, Miller CC, et al. Metabolic Syndrome but not Obesity Adversely Affects Outcomes after Open Aortoiliac Bypass Surgery. Ann Vasc Surg. 2017. PMID: 28887251. doi:10.1016/j.avsg.2017.08.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。